Skip to main content

Indian Pharma Network

FARESTON (Toremifene)

  • Medicine Name: FARESTON
  • Active Ingredient (API): Toremifene
  • Dosage Form & Strength: Tablets: 60 mg toremifene (as 88.5 mg toremifene citrate), blister packs of 30 (EU) or bottles of 30 (US generics)
  • Manufactured By: Orion Corporation, Finland (EU licence holder); US generic toremifene by Rising Pharma and Novadoz

Medical Uses

FARESTON (toremifene) is a hormone tablet for metastatic breast cancer in women who have gone through menopause. The US label covers tumours that are oestrogen-receptor positive or whose receptor status is unknown. The European licence describes it as first-line hormone treatment for hormone-dependent metastatic disease and says it is not recommended when the tumour is oestrogen-receptor negative.

Toremifene belongs to the same triphenylethylene family as tamoxifen. It sits on the oestrogen receptor in place of oestradiol, so the hormone can no longer push the tumour cells to copy their DNA and divide. The label notes that it can act partly like oestrogen in some tissues, which explains several of its side effects. It is broken down mainly by the liver enzyme CYP3A4 and has a long half-life of about 5 days, so a steady level builds up only after 4 to 6 weeks.

Three randomised trials compared 60 mg toremifene with tamoxifen in about 1,150 postmenopausal women. In the North American study the response rate was 21.3% with toremifene against 19.1% with tamoxifen, and median survival was 33.6 versus 34.0 months. The Eastern European study gave similar results; in the Nordic study time to progression was longer with tamoxifen (10.2 versus 7.3 months). Higher doses of 200–240 mg worked no better than 60 mg.

For a wider picture of hormone-positive disease, see our guide to advanced HR-positive, HER2-negative breast cancer. Newer oral options we also source include Orserdu (elacestrant) and Truqap (capivasertib).

Warnings & Precautions

  • Boxed warning, QT prolongation: toremifene lengthens the QT interval on the ECG in a dose-related way, which can trigger Torsade de pointes, fainting, seizures or death. It must not be used with congenital or acquired long QT, or with uncorrected low potassium or magnesium. An ECG and salts check before starting is sensible.
  • Medicines that also prolong QT (some antiarrhythmics, antipsychotics, antidepressants, antibiotics, ondansetron and granisetron) and strong CYP3A4 blockers should be avoided; ketoconazole nearly tripled toremifene exposure. Grapefruit should be avoided too. Strong enzyme inducers such as rifampicin, carbamazepine or St John’s wort lower its level.
  • Calcium and tumour flare: women with bone metastases can develop high calcium and bone pain in the first weeks. A flare is not treatment failure, but severe hypercalcaemia means the tablets are stopped. Thiazide water tablets add to the calcium risk.
  • Womb lining: endometrial thickening, polyps and cancer have been reported, so a gynaecological check is advised before starting and once a year. Abnormal vaginal bleeding should be reported.
  • Liver injury, including jaundice and fatty liver, has been reported; liver tests, calcium and blood counts are checked from time to time. Women with a history of blood clots are generally not treated with it. In Europe the labels also exclude severe liver failure and existing endometrial hyperplasia for long-term use.
  • With warfarin-type blood thinners bleeding time can rise sharply, so the European label advises avoiding the combination.
  • In the North American trial the most common side effects were hot flashes (35%), sweating (20%), nausea (14%), vaginal discharge (13%) and dizziness (9%); only about 1% stopped because of side effects. It can harm an unborn baby, so premenopausal women need effective non-hormonal contraception and it is not used during breastfeeding.

Documentation & Availability

How many packs does a patient need?

The dose is one 60 mg tablet a day, with or without food, usually continued until the disease progresses. One pack of 30 tablets lasts a month, so many families order two or three months at a time to avoid gaps.

What should be sent with the enquiry?
  • Oncologist’s prescription naming toremifene 60 mg daily and the planned duration
  • Biopsy or IHC report showing the oestrogen-receptor status
  • A recent ECG and potassium/magnesium values, which the doctor will want before starting
  • Patient ID proof and delivery address

The tablets are imported for one named patient on the basis of these papers.

How are the tablets stored?

The European blister pack needs no special storage and has a three-year shelf life; the US label says to keep the tablets at room temperature (25 °C) away from heat and light. No cold chain is needed.

Is toremifene sold in India?

We could not find toremifene on Indian pharmacy listings or an Indian approval record (checked November 2026). Some Indian firms make it only for export to the US, so for use in India the tablets are brought in against a prescription.

Sourcing & Delivery

Kyowa Kirin stopped distributing the FARESTON brand in the US at the end of August 2024, but the drug itself is still made. Orion’s FARESTON packs remain authorised in the European Union, and FDA-approved generic toremifene 60 mg tablets are marketed in the US. We tell you which source is available at the time of your order and supply only sealed original packs with batch and expiry details.

To check FARESTON (toremifene) price in India or to order, call +91 96548 60915 or +91 93100 90915, message us on WhatsApp at +91 98104 69557, use the toll-free line 1800 1200 365, or write to info@indianpharmanetwork.in.

Global Approval Status:

  • United States: FDA-approved on 29 May 1997 (NDA 020497); the brand is now listed as discontinued, not for safety reasons. Generic tablets (ANDA 208813 and 212818) are approved.
  • European Union: authorised since 14 February 1996; Orion Corporation, Finland, holds the licence.
  • India: no approved or marketed product found.

Sources:

Information last checked: November 2026.

FAQ

What is FARESTON used for?

Hormone-sensitive metastatic breast cancer in women after menopause.

Is toremifene the same as tamoxifen?

No, but it is a close chemical relative and works on the oestrogen receptor in a similar way. In trials the two gave broadly similar results.

Why is an ECG needed?

Toremifene can prolong the QT interval of the heartbeat, so doctors check the ECG and blood salts before and during treatment.

How long does treatment last?

Usually as long as the cancer stays under control and side effects are acceptable.

Who makes FARESTON?

Orion Corporation of Finland; Kyowa Kirin distributed it in the US until 2024.

Is FARESTON still available after the US brand stopped?

Yes. The European packs remain authorised and generic toremifene tablets are approved in the US.

Contact Patient Support

If you have any questions or need any help, contact our Patient Support Team. We will get in touch with you within 24 hours from Monday to Friday between 9:00 and 10:00 CET.

Disclaimer

All Trademarks and Brands that appear on the website belong to their respective owners and indianpharmanetwork does not lay any claim on them we only provide Information.

Product Enquiry